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Background: There is scanty guidance in the literature on the management of patients
with glutamic acid decarboxylase (GAD65) antibody associated autoimmune epilepsy
(GAD-epilepsy). GAD-epilepsy is a rare distinct neurological syndrome with a wide clinical
spectrum.We describe six GAD-epilepsy patients with special emphasis on the treatment
timing and the relationship between immunologic and anti-epileptic therapy.
Methods: Six patients diagnosed with GAD-epilepsy in Tampere University Hospital
who had received immunotherapy from 2013 to 2017 were retrospectively analyzed
from patient records. Data about symptom onset, including antibody levels, magnetic
resonance imaging (MRI), electroencephalograms, immunotherapy and anti-epileptic
treatment timing and treatment responses were collected and analyzed. Kruskall-Wallis
test was used in the statistical evaluation.
Results: All patients were female aged 9–54 at symptom onset. Three had
hypothyroidism, none had diabetes, two had migraine. Five patients had very high
(>2,000 IU/ml) and one had high (52–251 IU/ml) GAD65 antibody titers. All patients
presented with seizure disorders. Patients who received early initiation of immunotherapy
(3–10 months) responded well to treatment; patients in whom the immunotherapy
was started later (15–87 months) did not respond (p = 0.0495). The first patient was
seizure-free after 1 year of regular intravenous immunoglobulin and one antiepileptic drug
(AED). The second patient developed unilateral temporal lobe T2 signal changes in MRI;
she responded well to immunotherapy, experiencing a significant reduction in seizure
frequency and resolution of MRI abnormalities. However, seizures continued despite
trials with several AEDs. The third patient responded well to immunoadsorption and
rituximab with one AED, with lowering of GAD65 titers (from >2,000 to 300). There was
a long delay in the diagnosis of GAD-epilepsy in the three patients who had developed
refractory epilepsy, one with hippocampal sclerosis. They all received immunotherapy
but none responded. However, AED modification or vagus nerve stimulation
reduced the seizure frequency in two patients. Epilepsy surgery was ineffective.
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Conclusions: These results highlight the importance of early detection of GAD65
antibodies in refractory epilepsy as immunotherapy can be effective if administered in
the early stages of the disease when it can prevent permanent brain tissue damage.
Keywords: clinicalmanagement, glutamic acid decarboxylase antibody, limbic encephalitis, autoimmune epilepsy,
case series
INTRODUCTION
Autoimmunity is increasingly being recognized as a cause of
epilepsy (1). Glutamic acid decarboxylase 65-kilodalton isoform
(GAD65) antibodies have been associated with multiple non-
neurological and neurological syndromes including autoimmune
epilepsy (2).
GAD65 is an intracellular antigen, highly expressed in the
presynaptic terminals of inhibitory neurons in the central
nervous system (CNS) and in pancreatic β-cells (3). GAD65
antibodies possibly serve as a surrogate marker for organ
specific autoimmune disorders mediated by cytotoxic T cells
(4). However, there might also be some currently unknown
pathogenic surface-antigens targeted against hippocampi co-
existing with the GAD65 antibody and contributing to temporal-
lobe epilepsy (TLE) (5). Furthermore, the related pathological
processes can lead to hippocampal sclerosis and refractory
epilepsy (6). Moreover, widespread white matter changes have
been observed in GAD65 antibody related limbic encephalitis
(LE) (7).
Recently, anti-neuronal antibodies were detected in 20.5% of
epilepsies of unknown etiology and of these, 64% were high titer
GAD65 antibodies (8). Previously, it has been estimated that
between 1.7% (9) and 8.7% (10) of epilepsy patients are harboring
GAD65 antibodies.
GAD65 antibody associated autoimmune epilepsy (GAD-
epilepsy) is a rare but distinct neurological syndrome with a wide
clinical spectrum ranging from mild non-pharmacoresistant
epilepsy (10) to refractory TLE (11), LE (12), and also extra-
limbic encephalitis (ELE) (13). It seems that indolent GAD65
autoimmunity can develop into more severe forms over time
(14).
The literature contains only a few case reports dealing with
the management of refractory GAD-epilepsy (15). In addition
to anti-epileptic drugs (AEDs), a plethora of immunotherapies
has been tried with variable or unsatisfactory results (11, 15, 16).
Overall, the response to immunotherapy is poor and only a few
patients achieve seizure-freedom (17).
Since there is no clear guidance in the literature with respect to
the timing or on the combination of immunotherapy with AEDs
in the management of GAD-epilepsy, here we describe six GAD-
epilepsy cases treated with immunotherapy during different
disease stages and compare the results of immunotherapy with
those achieved by AEDs.
MATERIALS AND METHODS
Study Cohort
Patients treated in Tampere University Hospital Department of
Neurology for GAD-epilepsy between the years 2012 and 2017
were studied. The clinical data was analyzed retrospectively from
patient records. The initial diagnosis was suspected due to the
clinical symptoms and then supported by highly elevated titers
of serum GAD65 antibodies. Written informed consent was
obtained from the participants for the publication of this case
series.
Statistics
All statistical calculations were done in R version 3.4.3 (www.r-
project.org). Kruskall-Wallis test was used to compare treatment
results in immunotherapy responders vs. non-responders.
Laboratory and Imaging Studies
GAD65 antibody levels were analyzed in Fimlab laboratories
(Tampere, Finland) with standard clinical methods. In most
patients, Euroimmun (Luebeck, Germany) anti-GAD ELISA
(IgG) was used according to the manufacturer’s protocol. Prior
to 2014, the Medizym (Berlin, Germany) anti-GAD ELISA
(IgG) was used according to the manufacturer’s protocol. Most
serum and cerebrospinal fluid (CSF) neuronal autoantibody
panels were determined in Wieslab (Malmö, Sweden) with
standard methods. In patient 1, CSF neuronal antibodies were
analyzed in the Institut D’Investigacions Biomédiques August Pi
I Sunyer, (Hospital Clinic, University of Barcelona, Spain). Other
laboratory studies were undertaken with standard laboratory
methods at Fimlab laboratories. Brain magnetic resonance
images (MRI) were obtained according to a dedicated epilepsy
protocol on a 3 Tesla scanner. Electroencephalograms (EEG)
were obtained with standard protocols.
Therapeutic Interventions
Immunotherapy, including immunoadsorption, was
administered in all patients by following generally accepted
clinical principles. Accordingly, AED treatment was provided
to all patients in order to achieve maximum seizure control
and tolerability. Selective amygdalo-hippocampectomy (SAH)
and vagus nerve stimulator (VNS) were offered to some drug-
resistant patients after they had undergone comprehensive
pre-surgical diagnostics according to the current standards.
Treatment Outcomes
Outcome variables were the seizure or other main symptom
frequencies estimated from patient records such that an over
50% symptom reduction was considered as a good treatment
response; changes in the GAD65 antibody titer levels were also
determined.
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TABLE 1 | Individual patient characteristics, serological and cerebrospinal fluid studies.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age at onset, years 54 19 20 9 14 16
Sex Female Female Female Female Female Female
Symptom onset 2014/2 2012/7 2014/6 2007/12 2011/3 2014/1
Immunotherapy initiated 2014/5 2013/5 2014/10 2015/3 2012/6 2016/3
Comorbidities Hypothyroidism Migraine Hypothyroidism,
migraine
Hypothyroidism - -
GAD65 ab, serum, IU/ml 52–251 over 2,000 over 2,000 over 2,000 over 2,000 over 2,000
GAD65 ab, CSF Negative Positive Negative Negative Positive Not done
Serum studies, positive TPO, VGKC (low),
B2GP (low)*#£$%′′
All negative¤$#+x All negativeµ#−x&z ICA (5120 IU/ml)*£#
∧ i ANA*#£
∧x& ANA*#
′′c
CSF studies, positive VGKC (low)* All negative¤! All negativeµ All negative* All negative* All negative*
CSF (WBC, protein, IgG-index,
oligoclonal bands)
1, 1443-923, elevated,
no
11-3, normal, elevated,
yes
All normal Normal, normal,
normal, yes
Normal, elevated,
elevated, yes
6, normal, normal,
yes
The individual laboratory studies are indicated with superscripts; only positive results are shown.
ab, antibody; aCL, anticardiolipin ab; ANA, anti-nuclear antibody; ANCA, anti-neutrophil cytoplasmic antibody; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; B2GP,
Beta-2 Glycoprotein 1 Antibodies; caspr2, contactin-associated protein-like 2; CCP, cyclic citrullinated peptide ab; CSF, cerebrospinal fluid; C, complement; DNA, Deoxyribonucleic acid;
ENA, Extractable nuclear antigen; GABA, gamma-aminobutyric acid; GAD65, Glutamic acid decarboxylase 65-kilodalton isoform; HbA1c, Hemoglobin A1c; HHV, Human herpesvirus;
HIV, Human immunodeficiency virus; HSV-PCR, herpes simplex virus polymerase chain reaction; ICA, islet cell antibodies; LGI1, leucine-rich glioma inactivated 1; mGluR, metabotropic
glutamate receptor; NMDA, N-Methyl-D-aspartate receptor; MPO, myeloperoxidase ab; PR3, anti-proteinase 3; RF, rheumatoid factor; RNP, ribonucleoprotein; SSA, anti-Sjögren’s-
syndrome-related antigen A; SSB, anti-Sjögren’s-syndrome-related antigen B; TPO, thyroid peroxidase; TSH, thyreotropin; TTGA, Tissue transglutaminase ab; VGKC, voltage gated
potassium channel; WBC, white blood cells; *AMPA-1, caspr2, GABA-B, LGI1, mGluR1, mGluR5, NMDA; #ampiphysin, ANA, ANCA, DNA, ENA $borrelia, aCL, B2GP; £CV2, Hu, Ma1,
Ma2, Ri, Sox1, Yo; ¤ NMDA,VGKC, AMPA-1, GABA-B, HHV-6; µNMDA, VGCK; %HIV, 14-3-3; +TTGA; −MPO; ′′TPO; ∧RNP, SSA, SSB; i ICA !HSV-PCR; xC3, C4; &RF; zCCP, HbA1c,
TSH, thyroxine; c, cryoglobulin.
RESULTS
All six patients were female aged 9–54 at symptom onset
(Table 1) and presented with seizure disorders (Table 2). Patients
1–3 displayed a positive response whereas patients 4–6 exhibited
a negative response to immunotherapy; in the former group, the
mean delay from symptom onset to immunotherapy initiation
was only 5.7 months (range= 3–10 months) whereas in the latter
group, it was significantly longer, 66 months (range = 15–87
months) p= 0.0495.
A 54-year-old woman (patient 1; Figure 1A) presented
in the emergency department with a few weeks’ history of
cognitive decline and fluctuating vertigo, aphasia and tremor.
The neurological examination detected a fine tremor in all
limbs and total aphasia. The EEG revealed non-convulsive status
epilepticus (NCSE) without definitive lateralizing or localizing
features and this was treated with intravenous immunoglobulin
(IVIg) and IV AEDs. The NCSE resolved within 24 h. However,
she experienced several relapses whichmostly started with speech
difficulties leading to total aphasia, confusion, anxiety, mild gait
abnormality and tremor. NCSE relapsed three times and of
these two were treated successfully with IVIg. One NCSE was
successfully treated with propofol. Ultimately, the patient was
suffering only a mild speech impairment and gait disturbance at
the end of her immunotherapy cycle. Because of no relapses for
3 years with IVIg, the gradual reduction of dosage and increase
of treatment interval is ongoing. The patient is still on AED
monotherapy.
A 19-year-old woman (patient 2; Figure 1B) was brought to
the emergency department with daily focal impaired awareness
seizures (FIAS) (18, 19) and complaints of memory impairment.
TLE was diagnosed and the patient was almost symptom-free for
6 months with one AED, experiencing only mild aura symptoms
once a month. Her seizure frequency increased and a second
AED was initiated but with no clear response. GAD-epilepsy
was diagnosed during further examinations and her response
to immunotherapy was dramatic, resulting in almost complete
resolution of seizures. A follow-up MRI revealed a novel left
temporomesial signal change and edema correlating with the
EEG findings (Figure 2). In later follow-up MRIs after repeated
immunotherapy, the signal changes had started to resolve and in
due course, disappeared completely. Amild memory impairment
was confirmed in the neuropsychological examination; this did
not respond to immunotherapy. The patient continued to have
only a few FIAS daily. Immunotherapy was eventually terminated
since it did not provide any further reduction in her seizure
activity and the MRI abnormalities had resolved. This caused
neither increase in seizure frequency nor worsening of her
condition. She is still experiencing regular FIAS and is being
treated with four AEDs.
A 20-year-old woman (patient 3; Figure 1C) presented in
the emergency department after focal to bilateral tonic-clonic
seizures (FBTCS). On arrival, she had mild left sided weakness
and aphasia which soon resolved and she was discharged. For
a few weeks before the seizure, she had experienced mild
cognitive symptoms, mainly confusion. Headache, left-sided
weakness and the feelings of confusion relapsed without there
being any seizures. GAD-epilepsy was diagnosed early and
immunotherapy initiated to prevent worsening of the symptoms.
AED was provided mainly for migraine prevention. There
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FIGURE 1 | Individual characteristics of treatment responses and therapies provided in the studied GAD-epilepsy patients are shown. X-axis shows the time-points in
months starting from symptom onset. The blue line displays seizures / no seizures. Dotted lines refer to the interventions. Orange dots are GAD65 antibody levels.
Discontinuation of therapies is shown in parenthesis. 4 wk means 4-week intervals. Patient 1 (A) responded well to early initiation of immunotherapy. With patient 2
(B), there was longer delay before immunotherapy and she continued to experience seizures even after several AED and immunotherapy trials. However, her MRI
pathology resolved. Patient 3 (C) responded well to immunoadsorption with decreasing of GAD65 antibody levels after every trial. Patients 4–6 (D–F) did not respond
to late immunotherapy. In patient 4, a vagus nerve stimulator ultimately reduced seizure levels. In patient 6, AED modification reduced her seizure levels. AED,
antiepileptic drugs; AZM, acetazolamide; AZP, azathioprine; CBZ, carbamazepine; CLB, clobazam; CP, Cyclophosphamide; ECZ, eslicarbazepine; GAD65, Glutamic
acid decarboxylase 65-kilodalton isoform; HCQ, hydroxychloroquine; IA, immunoadsorption; IVIG, intravenous immunoglobulin; LCM, lacosamide; LEV, levetiracetam;
LZP; lorazepam; MMF, mycophenolate mofetil; MP, methylprednisolone; OCZ, oxcarbazepine; PEH, phenytoin; PR, prednisolone; RTX, rituximab; SAH, selective
amygdalohippocampectomy; TPM, topiramate; VNS, vagus nerve stimulation: wk, week; VLP, sodium valproate; ZNS, zonisamide;.
was no clear response to the initial immunotherapies and
they had to be stopped due to adverse effects. The patient
started to suffer anxiety and fear-like emotions after a second
FBTCS. She was provided with secondary immunotherapy
with immunoadsorption (IA) and there was clear resolution
of symptoms and also a lowering of GAD65 antibody levels.
However, she continued to experience focal unaware seizures
(FAS) with mild right sided arm twitching and there was a
return of the high GAD65 antibody titer levels; therefore, IA was
repeated with a good response.
A 9-year-old girl (patient 4; Figure 1D) presented with
nausea, abdominal pain and excessive swallowing and TLE was
diagnosed. She was symptom-free with one AED for 1 year
until she started to have 40 FIAS on a monthly basis. Multiple
AEDs and epilepsy surgery did not reduce her seizure frequency.
High GAD65 antibody levels were detected when performing
an extensive serology panel before VNS implantation 7 years
after symptom onset. Since primary immunotherapy achieved
no effects, secondary immunotherapy with IA and rituximab
was tried but with no symptom relief and no effect on GAD65
antibody levels. Immunotherapy was discontinued and a VNS
implanted, which when combined with two AEDs, achieved an
initial response, i.e., the patient became seizure-free.
A 14-year-old girl (patient 5; Figure 1E) presented with FIAS
and TLE was diagnosed. Brain MRI revealed left hippocampal
sclerosis. Multiple AEDs and epilepsy surgery did not reduce
her seizure frequencies. GAD-epilepsy was diagnosed 15 months
after symptom onset. She received primary immunotherapy but it
offered no benefits. Some years later, IA and rituximab were tried
but these neither eased her symptoms nor reduced her antibody
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FIGURE 2 | (A) The coronal fluid attenuation inversion recovery (FLAIR) magnetic resonance (MRI) -image taken during the acute stage of the illness shows an
abnormally hyperintense and swollen head of the left hippocampus (arrow). (B) Five months later, the finding has mostly resolved, although slight hyperintensity of the
left hippocampal head can still be seen (arrow). (C) In a control image, 3 years and 8 months after the acute stage, the abnormal finding has totally resolved (arrow).
There are no signs of atrophy in the primarily affected area.
levels. She is still experiencing regular FIAS despite therapy with
three AEDs.
A 16-year-old girl (patient 6; Figure 1F) presented with
FBTCS, eczema and joint pain. Despite treatment with two
AEDs, she continued to experience FIAS and high serum GAD65
antibody levels were detected 26 months after symptom onset.
Primary immunotherapy had no effect on seizures and it was
discontinued due to adverse effects. Hydroxychloroquine eased
her joint symptoms and this therapy was continued but she still
experienced FIAS. With AED modification, her seizure levels
declined and thus secondary immunotherapy was not tried.
DISCUSSION
We have described the clinical management of six patients
with GAD-epilepsy. Three patients responded well to early
immunotherapy initiated within 10 months after symptom onset
and one patient’s brain MRI abnormalities resolved after regular
immunotherapy. Immunotherapy achieved no objective benefit
in three patients who already had developed refractory epilepsy.
Instead, AED modification or VNS implantation achieved better
clinical results than immunotherapy in patients in whom the
diagnosis of GAD-epilepsy had been delayed. Epilepsy surgery
was ineffective in these patients.
Even though the biological process is most likely a continuum,
our results suggest that the clinical course of GAD-epilepsy
forms three major stages. In the first stage, reversible acute
immunoactivation causes the first seizure (20). In this stage, the
main focus of management should be placed on immunotherapy
since this can prevent permanent brain tissue damage and
stop the epilepsy from becoming refractory, as was seen with
patients 1 and 3. In the second stage of GAD-epilepsy, there
is already subtle irreversible brain tissue damage (4), which
causes refractory epilepsy (Patient 2). During the second stage,
immunotherapy can still be highly effective as was seen with the
resolution of brain MRI abnormalities in patient 2. However, it
seems that after the resolution of the immunoactivation, the focus
in management should shift to managing the refractory epilepsy.
In the third stage, there has been progressive damage leading to
hippocampal sclerosis and to a more diffuse brain damage and
cognitive symptoms (7). In this stage, immunotherapy seems to
be ineffective and the emphasis should be on the management of
the refractory epilepsy.
All of the evidence surrounding the management of GAD-
epilepsy has been based on small case reports and the treatment
results have been variable (15). The patients in our study
largely resemble previous study populations with a female
sex predominance and young age. In patients with diabetes,
GAD65 antibody titer levels of over 200 IU/ml are considered
high (21). In GAD-epilepsy, both high and very high (over
1,000 IU/ml) GAD65 antibody titer levels have been detected
(2) which is in accordance with the findings in our patients.
CSF was abnormal in all but one of our patients. Especially
patients 2 and 5 showed significant immunoactivation in
the CSF. Malignancy is rarely associated with GAD-epilepsy
(15) as was also shown in our data. Many GAD65 antibody
positive patients harbor other autoantibodies indicative of
polyautoimmunity (22). Accordingly, two of our patients had
ANA and one harbored TPO-antibodies. GAD-epilepsy patients
can also develop diabetes or other neurological GAD65 antibody
associated syndromes (3) although this was not observed in our
patients. Even in non-diabetic patients, the GAD65 antibody
positivity is strongly associated with thyroid disease (23) which
was also present in 50% of our patients. Patient 1 had low titer
antibodies against the VGKC complex but tested negative for
Caspr2 and LGI1. This finding is of uncertain clinical value (24).
In our previous study, we did not detect the presence of VGKC
antibodies in GAD-epilepsy patients (25).
In most case reports, IVIg and MP are the standard first line
immunotherapies administered (11, 15, 26) in GAD-epilepsy as
was the case with our patients. Some patients have benefited
also from plasma exchange (PLEX) (26, 27). The effects of
IVIg and immunoadsorption have been usually unsatisfactory.
However, in many of these studies, there has been a long
delay from symptom onset to treatment (11, 26). We used
immunoadsorption successfully in patient 3. CSF-filtration has
also been tried, however with a long delay from symptom onset
(11). Second line therapy usually includes cyclophosphamide and
rituximab (11, 26). We administered rituximab as second line
therapy but not cyclophosphamide in view of its adverse effects in
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young female patients. Other immunosuppressive agents such as
azathioprine and mycophenolate mofetil (MMF) have often been
tried (11) with varying results, as also in our patients. Moreover,
natalizumab has been tried to block T-cell entry into the CNS
(11). In one case report, GAD-epilepsy was successfully managed
with basiliximab (28); this was attributed to a reduction in the
numbers of activated T-cells via interleukin-2 receptor blockade.
Rituximab has an indirect inhibiting effect on pathogenic T-cells
(29) which could in part explain its effect as the pathology of
GAD-epilepsy seems to be mediated by cytotoxic T cells (4).
It is generally accepted that immunotherapy in GAD-epilepsy
should be initiated as soon as possible (15), however there is no
clear evidence defining when immunotherapy will no longer be
effective. In many previous studies, there has been a long delay
to diagnosis and immunotherapy initiation. For example, when
there was a 4.5 (±0.4) year delay in immunotherapy, only every
fifth patient showed any improvement (26). Furthermore, when
the median disease duration was 18 months, it was reported that
treatment results were poor (11).
Our results suggest that one obtains optimal results when
immunotherapy is initiated during the early stages of acute
immunoactivation when no brain MRI changes are yet visible as
was seen with patients 1 and 3. In some case reports it has been
shown similarly that early initiation of immunotherapy provides
complete seizure freedom (30). Thus, there is convincing
evidence that early immunotherapy can be effective in the first
stage of GAD-epilepsy.
In the second stage of GAD-epilepsy, there is already
irreversible brain tissue damage causing refractory epilepsy as
was observed in patient 2 and in many previous case series which
have demonstrated a poor treatment response to immunotherapy
(11). However, we could show that the already developed
brain MRI abnormalities could be resolved after regular
immunotherapy. In some case reports, immunotherapy has also
achieved a similar resolution of the MRI abnormalities (16, 31).
There is one case report describing the empirical initiation of
MP, IVIg, plasmapheresis, rituximab and cyclophosphamide in
refractory status epilepticus which later proved to be GAD-
epilepsy (16). After 1 month, that patient was almost symptom-
free with only occasional breakthrough seizures with regular
rituximab infusions and 5 AEDs with resolution of the MRI
abnormalities (16). This evidence is suggesting that even during
the second stage of GAD-epilepsy, immunotherapy can reverse
brain tissue damage and possibly prevent a more severe clinical
course of GAD-epilepsy. However, in this stage, the management
of GAD-epilepsy shifts from immunotherapy to managing the
refractory epilepsy.
In third stage of GAD-epilepsy, there already has occurred
permanent progressive damage, possibly hippocampal sclerosis
and permanent cognitive symptoms. One of our patients with late
GAD-epilepsy diagnosis had developed hippocampal sclerosis, as
has often been shown before (6) as the cytotoxic process seems
to initially involve limbic areas (4). Moreover, widespread white
matter changes have been detected inGAD-LE (7) suggesting that
there is also a more widespread pathology. Late immunotherapy
in refractory GAD-epilepsy had little effect, which is in line
with previous evidence (26). However, there is one case report
which claimed that PLEX exerted a clear effect 7 years after
symptom onset even though MP and IVIg had no effect (27)
and in one study, basiliximab showed temporal resolution of
seizures also 7 years after diagnosis (28). For these reasons,
immunotherapy should be tried at least shortly, even in late
GAD-epilepsy diagnosis.
AED selection in GAD-epilepsy is undertaken according to
the normal clinically accepted principles in attempts to achieve
maximum seizure control and tolerability (15). Only a few GAD-
epilepsy patients become seizure-free exclusively with AEDs
(32). AEDs also have immunomodulatory effects which could
in part explain their effect on the autoimmune epilepsies (32).
All but one of our patients required multiple AEDs. However,
after the symptoms were controlled with immunotherapy, some
AEDs could be discontinued. Moreover, we recommend that
when immunotherapy is no longer effective, it is advisable to
concentrate on the management of epilepsy. One of our patients
responded well to VNS which has not been shown previously
in GAD-epilepsy patients. Epilepsy surgery was performed on
two of our patients but it exerted no clear effect on seizure
levels and this resembles the situation in other GAD-epilepsy
patients (6). The better response to VNS than to epilepsy surgery
might be because of the diffuse pathology in GAD-epilepsy (7).
In all three of our refractory patients, however, the epileptic
focus was eventually bilateral, pointing to an insidious continuing
cytotoxic process. It seems that early immunotherapy can halt the
destructive process and epilepsy surgery could be avoided.
A clear limitation of our study is the low number of patients
and the retrospective nature of the study design. However, GAD-
epilepsy is a rare entity and large patient materials are difficult
to obtain. Moreover, our patients showed varying symptoms.
Previously only GAD-TLE or GAD-LE patients have been
studied. In this study, we combined GAD-epilepsy patients with
different presentations and also the diagnoses had been made
with varying delays. However, this also shows that GAD-epilepsy
should be suspected in many different clinical scenarios and we
have provided new evidence on the timing of the treatments.
In conclusion, these results highlight the importance of
early detection of GAD65 antibodies in refractory epilepsy as
immunotherapy can be effective during the early stages of the
disease and it can possibly prevent the development of permanent
brain tissue damage.
ETHICS STATEMENT
A case report is a medical/educational activity that does not
meet the DHHS definition of research, which is: a systematic
investigation, including research development, testing and
evaluation, designed to develop or contribute to generalizable
knowledge. Therefore, the activity does not have to be reviewed
by a IRB.
AUTHOR CONTRIBUTIONS
K-MM, AH, AB, JP conceived and designed the study. K-MM,
AH, AB, JP analyzed the data. AB analyzed MRI images. K-MM,
AH, AB, JP wrote the paper.
Frontiers in Neurology | www.frontiersin.org 7 July 2018 | Volume 9 | Article 579
Mäkelä et al. Clinical Management of GAD-Epilepsy
REFERENCES
1. Bauer J, Becker AJ, ElyamanW, Peltola J, Ruegg S, TitulaerMJ, et al. Innate and
adaptive immunity in human epilepsies. Epilepsia (2017) 58(Suppl. 3):57–68.
doi: 10.1111/epi.13784
2. Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K, Palmio J, et al. Autoantibodies
to glutamic acid decarboxylase in patients with therapy-resistant epilepsy.
Neurology (2000) 55:46–50. doi: 10.1212/WNL.55.1.46
3. McKeon A, Tracy JA. GAD65 neurological autoimmunity. Muscle Nerve
(2017) 56:15–27. doi: 10.1002/mus.25565
4. Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I, Graus F, et
al. Immunopathology of autoantibody-associated encephalitides: clues for
pathogenesis. Brain (2012) 135:1622–38. doi: 10.1093/brain/aws082
5. Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas
MC. GAD65 epitope mapping and search for novel autoantibodies in
GAD-associated neurological disorders. J Neuroimmunol. (2015) 281:73–7.
doi: 10.1016/j.jneuroim.2015.03.009
6. Glover RL, DeNiro LV, Lasala PA, Weidenheim KM, Graber JJ, Boro
A. ILAE type 3 hippocampal sclerosis in patients with anti-GAD-
related epilepsy. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e122.
doi: 10.1212/NXI.0000000000000122
7. Wagner J, Schoene-Bake JC, Witt JA, Helmstaedter C, Malter MP, Stoecker
W, et al. Distinct white matter integrity in glutamic acid decarboxylase
and voltage-gated potassium channel-complex antibody-associated limbic
encephalitis. Epilepsia (2016) 57:475–83. doi: 10.1111/epi.13297
8. Dubey D, Alqallaf A, Hays R, Freeman M, Chen K, Ding K, et al.
Neurological autoantibody prevalence in epilepsy of unknown etiology.
JAMA Neurol. (2017) 74:397–402. doi: 10.1001/jamaneurol.2016.
5429
9. Brenner T, Sills GJ, Hart Y, Howell S, Waters P, Brodie MJ, et al. Prevalence
of neurologic autoantibodies in cohorts of patients with new and established
epilepsy. Epilepsia (2013) 54:1028–35. doi: 10.1111/epi.12127
10. Falip M, Carreno M, Miro J, Saiz A, Villanueva V, Quilez A, et al.
Prevalence and immunological spectrum of temporal lobe epilepsy with
glutamic acid decarboxylase antibodies. Eur J Neurol. (2012) 19:827–33.
doi: 10.1111/j.1468-1331.2011.03609.x
11. Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter
C, et al. Treatment of immune-mediated temporal lobe epilepsy with
GAD antibodies. Seizure (2015) 30:57–63. doi: 10.1016/j.seizure.2015.
05.017
12. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to
glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol.
(2010) 67:470–8. doi: 10.1002/ana.21917
13. Najjar S, PearlmanD,Najjar A, Ghiasian V, ZagzagD, DevinskyO. Extralimbic
autoimmune encephalitis associated with glutamic acid decarboxylase
antibodies: an underdiagnosed entity? Epilepsy Behav. (2011) 21:306–13.
doi: 10.1016/j.yebeh.2011.03.038
14. Fauser S, Uttner I, Arino H, ScherbaumWA, Saiz A, Lewerenz J. Long latency
between GAD-antibody detection and development of limbic encephalitis–a
case report. BMC Neurol. (2015) 15:177. doi: 10.1186/s12883-015-0435-9
15. Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, et al.
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy.
Epilepsy Behav (2018) 80:331–6. doi: 10.1016/j.yebeh.2018.01.021
16. Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory
status epilepticus and glutamic acid decarboxylase antibodies in adults:
presentation, treatment and outcomes. Epileptic Disord. (2016) 18:34–43.
doi: 10.1684/epd.2016.0797
17. Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and
other inflammatory encephalitis. Curr Opin Neurol. (2017) 30:345–53.
doi: 10.1097/WCO.0000000000000449
18. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, et
al. Instruction manual for the ILAE 2017 operational classification
of seizure types. Epilepsia (2017) 58:531–42. doi: 10.1111/epi.
13671
19. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE,
et al. Operational classification of seizure types by the International
League Against Epilepsy: Position Paper of the ILAE Commission for
Classification and Terminology. Epilepsia (2017) 58:522–30. doi: 10.1111/epi.
13670
20. Liimatainen S, Lehtimaki K, Palmio J, Alapirtti T, Peltola J. Immunological
perspectives of temporal lobe seizures. J Neuroimmunol. (2013) 263:1–7.
doi: 10.1016/j.jneuroim.2013.08.001
21. Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, et
al. Inverse Relationship between organ-specific autoantibodies and systemic
immune mediators in type 1 diabetes and type 2 diabetes: action LADA 11.
Diabetes Care (2016) 39:1932–9. doi: 10.2337/dc16-0293
22. Liimatainen S, Peltola M, Sabater L, Fallah M, Kharazmi E, Haapala AM, et al.
Clinical significance of glutamic acid decarboxylase antibodies in patients with
epilepsy. Epilepsia (2010) 51:760–7. doi: 10.1111/j.1528-1167.2009.02325.x
23. Sorgjerd EP, Thorsby PM, Torjesen PA, Skorpen F, Kvaloy K, Grill V. Presence
of anti-GAD in a non-diabetic population of adults; time dynamics and
clinical influence: results from the HUNT study. BMJ Open Diabetes Res Care
(2015) 3:e000076. doi: 10.1136/bmjdrc-2014-000076
24. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical
approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016)
15:391–404. doi: 10.1016/S1474-4422(15)00401-9
25. Liimatainen S, Peltola J, Hietaharju A, Sabater L, Lang B. Lack of
antibodies to NMDAR or VGKC-complex in GAD and cardiolipin
antibody-positive refractory epilepsy. Epilepsy Res. (2014) 108:592–6.
doi: 10.1016/j.eplepsyres.2013.12.015
26. Hansen N, Widman G, Witt JA, Wagner J, Becker AJ, Elger CE, et al. Seizure
control and cognitive improvement via immunotherapy in late onset epilepsy
patients with paraneoplastic versus GAD65 autoantibody-associated limbic
encephalitis. Epilepsy Behav (2016) 65:18–24. doi: 10.1016/j.yebeh.2016.10.016
27. Mazzi G, Roia DD, Cruciatti B, Mata S, Catapano R. Plasma exchange for anti
GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci.
(2008) 39:229–33. doi: 10.1016/j.transci.2008.09.005
28. Widman G, Golombeck K, Hautzel H, Gross CC, Quesada CM, Witt JA, et al.
Treating a GAD65 antibody-associated limbic encephalitis with basiliximab: a
case study. Front Neurol. (2015) 6:167. doi: 10.3389/fneur.2015.00167
29. Dalakas MC. B cells as therapeutic targets in autoimmune neurological
disorders.Nat Clin Pract Neurol. (2008) 4:557–67. doi: 10.1038/ncpneuro0901
30. Incecik F, Herguner OM, Besen S, Yilmaz M. Autoimmune encephalitis
associated with glutamic acid decarboxylase antibodies: a case series. Acta
Neurol Belg. (2018). doi: 10.1007/s13760-018-0880-5. [Epub ahead of print].
31. Kobayakawa Y, Tateishi T, Kawamura N, Doi H, Ohyagi Y, Kira J. A case of
immune-mediated encephalopathy showing refractory epilepsy and extensive
brain MRI lesions associated with anti-glutamic acid decarboxylase antibody.
Rinsho Shinkeigaku (2010) 50:92–7. doi: 10.5692/clinicalneurol.50.92
32. Feyissa AM, Lopez Chiriboga AS, Britton JW. Antiepileptic drug therapy in
patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm.
(2017) 4:e353. doi: 10.1212/NXI.0000000000000353
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Mäkelä, Hietaharju, Brander and Peltola. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neurology | www.frontiersin.org 8 July 2018 | Volume 9 | Article 579
